Dianthus Therapeutics, Inc. Common Stock (DNTH) Stock Price

DNTHStock

$72.09+100.25%52W

Market Cap$3.94B

P/E—

PEG Ratio—

Div yield—

Beta2.00

DNTH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-33.95%

Price vs S&P 500 (4W)-23.95%

VGM Score40.34

Book Value / Share (Quarterly)$21.39

P/TBV (Annual)1.61x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.84

Price vs S&P 500 (YTD)63.01%

Net Profit Margin (TTM)-10096.95%

EPS (TTM)$-4.15

10-Day Avg Trading Volume0.94M

EPS Excl Extra (TTM)$-4.15

EPS (Annual)$-4.20

ROI (Annual)-32.90%

Cash / Share (Quarterly)$16.18

Revenue Growth QoQ (YoY)294.30%

ROA (Last FY)-30.58%

Revenue Growth TTM (YoY)-60.77%

EBITD / Share (TTM)$-4.66

ROE (5Y Avg)-39.22%

Operating Margin (TTM)-11441.39%

Cash Flow / Share (Annual)$-2.99

P/B Ratio3.44x

P/B Ratio (Quarterly)4.55x

Net Income / Employee (Annual)$-1,764,500

EV / Revenue (TTM)2059.75x

Net Interest Coverage (TTM)-57.94x

ROA (TTM)-21.55%

EPS Incl Extra (Annual)$-4.20

Current Ratio (Annual)13.32x

Quick Ratio (Quarterly)25.80x

3-Month Avg Trading Volume1.00M

52-Week Price Return100.25%

Revenue / Employee (TTM)$20,700

Tangible BV / Share (Quarterly)$12.04

P/S Ratio (Annual)1980.51x

Asset Turnover (Annual)0.00x

52-Week High$117.88

EPS Excl Extra (Annual)$-4.20

CapEx CAGR (5Y)-11.84%

Tangible BV CAGR (5Y)16.06%

26-Week Price Return-24.04%

Quick Ratio (Annual)13.16x

13-Week Price Return-31.73%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)26.10x

Enterprise Value$3.92B

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)3.60%

Revenue / Employee (Annual)$22,100

Pretax Margin (Annual)-7973.33%

Cash / Share (Annual)$9.35

3-Month Return Std Dev48.15%

Net Income / Employee (TTM)$-2,089,600

ROE (Last FY)-32.90%

EPS Basic Excl Extra (Annual)$-4.20

Receivables Turnover (TTM)26.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.15

ROI (TTM)-22.53%

P/S Ratio (TTM)2117.81x

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$27.96

Price vs S&P 500 (52W)84.72%

Year-to-Date Return74.93%

5-Day Price Return-11.62%

EPS Normalized (Annual)$-4.20

ROA (5Y Avg)-33.44%

Net Profit Margin (Annual)-7973.33%

Month-to-Date Return-18.13%

Cash Flow / Share (TTM)$-14.53

EBITD / Share (Annual)$-4.60

Operating Margin (Annual)-8739.34%

ROI (5Y Avg)-39.22%

EPS Basic Excl Extra (TTM)$-4.15

P/TBV (Quarterly)0.96x

P/B Ratio (Annual)3.58x

Pretax Margin (TTM)-10096.95%

Book Value / Share (Annual)$11.42

Price vs S&P 500 (13W)-34.42%

Beta2.00x

Revenue / Share (TTM)$0.03

ROE (TTM)-22.53%

52-Week Low$32.22

vGradeF

gGradeC

mGradeC

vgmGradeC

DNTH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.91	-$0.90	+0.96%(+$0.01)
Q1 2026	May 5, 2026	-$1.10	-$0.85	+22.93%(+$0.25)
Q4 2025	Mar 9, 2026	-$1.03	-$1.43	-38.64%(-$0.40)
Q3 2025	Nov 5, 2025	-$0.90	-$0.97	-7.95%(-$0.07)
Q2 2025	Aug 7, 2025	-$0.87	-$0.88	-1.54%(-$0.01)

DNTH Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.41

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
DNTHDianthus Therapeutics, Inc. Common Stock	F	C	C	2117.8x	-60.8%	—	—	$72.09
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Dianthus Therapeutics, Inc. Common Stock

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation monoclonal antibody therapies targeting complement for severe autoimmune and inflammatory diseases. The company's lead candidate, DNTH103, is a subcutaneous C1s inhibitor designed to offer improved selectivity and potency over existing complement therapies. The team brings substantial biotechnology and pharmaceutical expertise to advance its pipeline.

DNTH Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.95

Revenue estimate$366,420

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

DNTH Insider Transactions

SellSep 1, 2026
RANDHAWA SIMRAT
Officer
Shares: 23,124Value: $2.46M
SellAug 19, 2026
READ SIMON J.
Director
Shares: 2,778Value: $326,554
SellAug 10, 2026
VENESS ADAM M
General Counsel
Shares: 20,000Value: $2.21M
SellAug 10, 2026
MCGEORGE ANNE
Director
Shares: 7,750Value: $844,822
SellAug 10, 2026
READ SIMON J.
Director
Shares: 2,777Value: $304,232

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

RGCRegencell Bioscience Holdings Limited Ordinary SharesPharmaceutical Preparations
CSWCSW Industrials, Inc.Adhesives & Sealants
PRMPerimeter Solutions, Inc.Chemicals
DFTXDefinium Therapeutics, Inc. Common SharesPharmaceutical Preparations
CBTCabot CorporationIndustrial Chemicals
ADPTAdaptive Biotechnologies Corporation Common StockBiological Products
IPARInterparfums, Inc. Common StockCosmetics & Toiletries
AVNTAvient CorporationPlastics & Resins

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.4

Strong Buy

Consensus rating

52-Week Range

Low$32.22

High$117.88